Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer

26 Feb 2025

Abstract excerpt

Breast cancer has constantly been the leading causes of death in women, and hormone receptor (HR) positive, HER2 negative is the majority subtype. Histone deacetylase (HDAC) inhibitors (HDACi) have shown clinical benefit in HR ( +) breast cancer patients. The Hippo pathway is an important cellular pathway involving proliferation, cell contact, and cancer. Hippo pathway proteins YAP/TAZ are often viewed as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Hippo pathway signaling and YAP/TAZ
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40012020
DOI: 10.1186/s13148-025-01834-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancerPMID 40012020Read ↗

HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancerSemantic proximity Read ↗

Implications for precision medicine and the reciprocal control of microRNAs by Hippo and TAZ signaling in breast cancerSemantic proximity Read ↗

HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.Semantic proximity Read ↗

Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187Semantic proximity Read ↗

HDAC Inhibitors for the Therapy of Triple Negative Breast CancerSemantic proximity Read ↗

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axisSemantic proximity Read ↗

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast CancerSemantic proximity Read ↗

ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.Semantic proximity Read ↗

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.Semantic proximity Read ↗

Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer PatientsSemantic proximity Read ↗

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast CancerSemantic proximity Read ↗

KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.